Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
MDGL

MDGL - Madrigal Pharmaceuticals Inc Stock Price, Fair Value and News

276.01USD-0.71 (-0.26%)Market Closed

Market Summary

MDGL
USD276.01-0.71
Market Closed
-0.26%

MDGL Alerts

  • 2 major insider sales recently.

MDGL Stock Price

View Fullscreen

MDGL RSI Chart

MDGL Valuation

Market Cap

5.9B

Price/Earnings (Trailing)

-13.24

Price/Sales (Trailing)

12.8K

Price/Free Cashflow

-15.04

MDGL Price/Sales (Trailing)

MDGL Profitability

Return on Equity

-52.22%

Return on Assets

-41.05%

Free Cashflow Yield

-6.65%

MDGL Fundamentals

MDGL Revenue

Revenue (TTM)

363.0K

MDGL Earnings

Earnings (TTM)

-444.3M

Earnings Growth (Yr)

-91.87%

Earnings Growth (Qtr)

-31.51%

Breaking Down MDGL Revenue

Last 7 days

-5.5%

Last 30 days

25.4%

Last 90 days

6.6%

Trailing 12 Months

13.1%

How does MDGL drawdown profile look like?

MDGL Financial Health

Current Ratio

9.39

Debt/Equity

0.14

Debt/Cashflow

-3.35

MDGL Investor Care

Shares Dilution (1Y)

16.53%

Diluted EPS (TTM)

-23.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20212.6M1.5M743.0K363.0K
20209.9M8.1M6.1M4.3M
201910.0M11.8M11.8M11.0M
20181.2M2.3M4.9M7.7M
2017000558.0K
20160000
20120000
201112.4M9.9M8.2M7.6M
20100101.1M58.0M14.8M
2009000144.2M

Tracking the Latest Insider Buys and Sells of Madrigal Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2024
waltermire robert e.
acquired
165,471
87.09
1,900
senior vp, chief pharma dev.
Jun 14, 2024
waltermire robert e.
sold
-532,000
280
-1,900
senior vp, chief pharma dev.
Jun 12, 2024
waltermire robert e.
acquired
175,840
87.92
2,000
senior vp, chief pharma dev.
Jun 12, 2024
waltermire robert e.
sold
-570,000
285
-2,000
senior vp, chief pharma dev.
Jun 11, 2024
craves fred b
gifted
-
-
-39,000
-
Jun 11, 2024
craves fred b
gifted
-
-
-45,852
-
May 21, 2024
waltermire robert e.
sold
-239,668
231
-1,036
senior vp, chief pharma dev.
May 14, 2024
craves fred b
acquired
2,316,840
103
22,489
-
May 14, 2024
craves fred b
sold
-4,787,400
212
-22,489
-

1–10 of 50

Which funds bought or sold MDGL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
unchanged
-
-465
3,468
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
215,000
2,057,000
-%
May 30, 2024
EULAV Asset Management
reduced
-15.38
-70,500
2,937,440
0.08%
May 30, 2024
CAMBRIDGE TRUST CO
unchanged
-
2,318
17,358
-%
May 28, 2024
Verity Asset Management, Inc.
reduced
-41.47
-201,860
420,321
0.23%
May 24, 2024
Cetera Investment Advisers
new
-
601,641
601,641
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
118,356
886,306
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
65.84
485,019
1,015,020
0.13%
May 20, 2024
Virtu Financial LLC
sold off
-100
-940,000
-
-%
May 17, 2024
Artal Group S.A.
new
-
29,509,800
29,509,800
0.75%

1–10 of 39

Are Funds Buying or Selling MDGL?

Are funds buying MDGL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MDGL
No. of Funds

Unveiling Madrigal Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 25, 2024
baker bros. advisors lp
9.99%
2,070,544
SC 13D/A
Feb 14, 2024
armistice capital, llc
0.25%
50,000
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
9.9%
2,288,888
SC 13G/A
Feb 14, 2024
paulson & co. inc.
5.6%
-
SC 13G/A
Feb 13, 2024
janus henderson group plc
14.7%
2,902,050
SC 13G/A
Feb 13, 2024
vanguard group inc
7.98%
1,574,742
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
1,212,562
SC 13G/A
Jan 22, 2024
state street corp
3.55%
700,739
SC 13G/A
Dec 13, 2023
bay city capital llc
2.9%
567,644
SC 13D/A
Nov 21, 2023
baker bros. advisors lp
9.99%
1,987,702
SC 13D/A

Recent SEC filings of Madrigal Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
4
Insider Trading
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
4
Insider Trading
Jun 13, 2024
144
Notice of Insider Sale Intent
Jun 13, 2024
4
Insider Trading
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 06, 2024
144
Notice of Insider Sale Intent
May 23, 2024
4
Insider Trading

Peers (Alternatives to Madrigal Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-3.00% -55.11%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
6.00% 71.52%
-4.86
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.7M
2.1M
15.15% 225.71%
-0.85
7.61
-13.45% 69.54%

Madrigal Pharmaceuticals Inc News

Latest updates
Investing.com3 hours ago
Defense World14 Jun 202409:27 pm
Investor's Business Daily05 Jun 202407:00 am
The Motley Fool21 May 202407:00 am

Madrigal Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q4
Revenue-13.3%52,00060,00091,000160,000432,000823,0001,204,0001,870,0002,214,0002,766,0003,005,0003,039,0002,979,0002,821,0001,166,000705,000216,000174,00092,00076,00059,000
Operating Expenses2.3%64,601,00063,160,00061,742,00052,979,00059,555,00058,786,00050,327,00038,005,00029,954,00024,195,00022,704,00018,119,00014,454,00011,333,0007,826,000------
  S&GA Expenses41.3%11,712,0008,287,00010,110,0007,209,0006,126,0005,494,0005,639,0004,605,0005,044,0004,748,0007,110,0005,746,0005,583,0005,122,0002,717,000------
Interest Expenses----------------------
Net Income-2.3%-64,549,000-63,100,000-61,651,000-52,546,000-59,123,000-57,963,000-49,023,000-36,135,000-27,740,000-21,429,000-19,699,000-15,080,000-11,475,000-8,512,000-6,460,000------
Net Income Margin-109.4%-666-318-153------------------
Free Cashflow-5.6%-48,164,000-45,606,000-46,883,000------------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets69.0%1,082641238302332363159216223273305328310287340388411442456470480
  Current Assets68.5%1,074637235302331361157215221272303326308285338387409440455469478
    Cash Equivalents523.0%62310062.0077.0011333259.0053.0042.0036.0049.0034.0044.0054.0010962.0067.0047.0089.0073.0047.00
  Inventory-1.00--------------------
  Net PPE12.2%2.002.001.000.001.001.001.001.001.001.001.001.001.001.001.001.001.001.000.000.000.00
Liabilities-1.6%23223521619918216514813377.0077.0070.0057.0049.0047.0050.0045.0026.0025.0016.0013.0011.00
  Current Liabilities-3.5%11411910010098.0011699.0084.0077.0077.0069.0057.0049.0047.0049.0045.0026.0025.0015.0012.0010.00
  Long Term Debt0.6%11611511599.0084.0049.0049.0049.00-------------
    LT Debt, Non Current0.6%11611511599.0084.0049.0049.0049.00-------------
Shareholder's Equity109.9%85140522.0010415019711.0084.00146196235271261240290343385417440457469
  Retained Earnings-11.0%-1,483-1,336-1,224-1,125-1,039-962-876-795-724-667-602-539-478-425-366-308-259-223-195-174-154
  Additional Paid-In Capital34.1%2,3351,7411,2461,2291,1901,160888880871863838810739665656650644640636631623
Shares Outstanding-3.9%20.0021.0018.0018.0018.0018.0017.0017.0017.0017.0017.0017.00---------
Float----3,158---985---819---1,130---884-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-86.6%-149,157-79,933-84,920-75,310-84,067-58,515-59,069-57,360-49,913-48,051-45,556-46,881-43,429-54,947-47,850-24,258-30,506-12,282-11,324-11,540-6,478
  Share Based Compensation34.0%19,90214,85212,66010,97311,2508,0828,1227,9447,4776,3566,2428,1796,0965,1345,0615,6894,8464,0324,9507,7556,022
Cashflow From Investing127.1%98,053-362,12350,199-3,732-186,86466,38765,13719,23655,92615,64340,091-27,325-33,464-4,79894,75319,36550,460-30,50728,26736,438-3,491
Cashflow From Financing19.5%573,706479,91619,58042,93052,690264,337-49,114-19,50321,09963,54167,0944,629350109--35.0011783.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MDGL Income Statement

2024-03-31
Condensed Consolidated Statements Of Operations - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 0$ 0
Operating expenses:  
Research and development71,237,00062,154,000
Selling, general and administrative80,800,00016,182,000
Total operating expenses152,037,00078,336,000
Loss from operations(152,037,000)(78,336,000)
Interest income8,334,0003,776,000
Interest expense(3,838,000)(2,336,000)
Net loss$ (147,541,000)$ (76,896,000)
Net loss per common share:  
Basic net loss per common share (in dollars per share)$ (7.38)$ (4.23)
Diluted net loss per common share (in dollars per share)$ (7.38)$ (4.23)
Basic weighted average number of common shares outstanding (in shares)20,001,56918,187,924
Diluted weighted average number of common shares outstanding (in shares)20,001,56918,187,924

MDGL Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 622,517$ 99,915
Marketable securities436,546534,216
Inventory8540
Prepaid expenses and other current assets14,0353,150
Total current assets1,073,952637,281
Property and equipment, net1,7421,553
Intangible assets, net5,0000
Right-of-use asset1,5861,713
Total assets1,082,280640,547
Current liabilities:  
Accounts payable21,52828,041
Accrued expenses92,27189,980
Lease liability542527
Total current liabilities114,341118,548
Long term liabilities:  
Loan payable, net of discount116,135115,480
Lease liability1,0451,186
Total long term liabilities117,180116,666
Total liabilities231,521235,214
Stockholders’ equity:  
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at September 30, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively00
Common stock, par value $0.0001 per share authorized: 200,000,000 at September 30, 2023 and December 31, 2022; 18,494,192 and 18,102,523 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively22
Additional paid-in-capital2,334,7601,741,153
Accumulated other comprehensive income (loss)(172)468
Accumulated deficit(1,483,831)(1,336,290)
Total stockholders’ equity850,759405,333
Total liabilities and stockholders’ equity$ 1,082,280$ 640,547
MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
 WEBSITEmadrigalpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES92

Madrigal Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Madrigal Pharmaceuticals Inc? What does MDGL stand for in stocks?

MDGL is the stock ticker symbol of Madrigal Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Madrigal Pharmaceuticals Inc (MDGL)?

As of Tue Jun 18 2024, market cap of Madrigal Pharmaceuticals Inc is 5.88 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart for subscribers.

What is the fair value of MDGL stock?

You can check MDGL's fair value in chart for subscribers. The fair value of Madrigal Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Madrigal Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Madrigal Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MDGL is over valued or under valued. Whether Madrigal Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Madrigal Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDGL.

What is Madrigal Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, MDGL's PE ratio (Price to Earnings) is -13.24 and Price to Sales (PS) ratio is 12.8 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Madrigal Pharmaceuticals Inc's stock?

In the past 10 years, Madrigal Pharmaceuticals Inc has provided 0.062 (multiply by 100 for percentage) rate of return.